Zobrazeno 1 - 10
of 11
pro vyhledávání: '"H Pieter van den Berg"'
Autor:
Danny Houtsma, Andre M. Bergman, Suzan Ras van Spijk, Irma M. Oving, Vincent van der Noort, Vincent O. Dezentjé, Paul Hamberg, Kim van der Zande, H. Pieter van den Berg, Milou Busard, Wilbert Zwart, Diederik ten Oever, Metin Tascilar, Aart Beeker, Jeantine M de Feijter
Publikováno v:
Journal of Clinical Oncology. 39:5059-5059
5059 Background: In the OSTRICh trial, poor-prognosis mCRPC patients were randomized between CBZ and ARTA, following progression on docetaxel (DOC) treatment. Methods: The OSTRICh trial is an open label, multicenter, phase IIb study. Patients with po
Autor:
Carolien H. Smorenburg, Juleon L.L.M. Coenen, Alfons J.M. van den Eertwegh, Aart Beeker, H. Pieter van den Berg, Winald R. Gerritsen, Walter L. Vervenne, Henk M.W. Verheul, Linda de Munck, Esther W. Bouman-Wammes
Publikováno v:
European Journal of Cancer, 90, pp. 1-9
Bouman-Wammes, E W, van den Berg, H P, de Munck, L, Beeker, A, Smorenburg, C H, Vervenne, W L, Coenen, J L L M, Verheul, H M W, Gerritsen, W R & van den Eertwegh, A J M 2018, ' A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial ', European Journal of Cancer, vol. 90, pp. 1-9 . https://doi.org/10.1016/j.ejca.2017.11.021
European Journal of Cancer, 90, 1-9
European Journal of Cancer, 90, 1-9. Pergamon
European journal of cancer (Oxford, England, 90, 1-9. Elsevier Limited
Bouman-Wammes, E W, van den Berg, H P, de Munck, L, Beeker, A, Smorenburg, C H, Vervenne, W L, Coenen, J L L M, Verheul, H M W, Gerritsen, W R & van den Eertwegh, A J M 2018, ' A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial ', European Journal of Cancer, vol. 90, pp. 1-9 . https://doi.org/10.1016/j.ejca.2017.11.021
European Journal of Cancer, 90, 1-9
European Journal of Cancer, 90, 1-9. Pergamon
European journal of cancer (Oxford, England, 90, 1-9. Elsevier Limited
Background Docetaxel is standard first-line chemotherapy for patients with metastatic castration–resistant prostate carcinoma (mCRPC). Docetaxel re-challenge has never been tested in a prospective randomised controlled study. As some studies suppor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46627d79ce31233731263293df40e564
https://hdl.handle.net/2066/183699
https://hdl.handle.net/2066/183699
Autor:
Andrzej Piwowar, Fransje Aa Valster, Jeffrey P.B.M. Braak, Marije Ie Appels, Frits van Coevorden, Niels H Nielsen, Johanna E.A. Portielje, Jeroen Buijsen, Petra Flygare, Marije Slingerland, Nicole C.T. van Grieken, Jetske M. Meerum Terwogt, Maartje Los, Mattias Elmlund, Henk Boot, Rob L. H. Jansen, Johanna W. van Sandick, A. Haringhuizen, Johannes J. Bonenkamp, Harm van Tinteren, Edwin P.M. Jansen, Henk H. Hartgrink, Jaap De Boer, Anouk K. Trip, Ge Jpm Jonkers, Marie Louise Jespersen, Cecillia Lagerbäck, Per Edlund, Marco B Polée, Mats Perman, J (Hans)-Martin Mb Otten, Marjan A Van Dijk, Danny Houtsma, A (Bert) Jan Ten Tije, Arnold Baars, Olaf Jl Loosveld, Maud M. Geenen, Maarten C.C.M. Hulshof, Gerrit-Jan Veldhuis, Erik W Muller, Geert-Jan Creemers, Annelie Je Vulink, Quirijn A. J. Eijsbouts, Annerie Slot, Diane Grootenboers, Hein Putter, Ellen M Hendriksen, Maurice J.C. van der Sangen, Fabiënne A. R. M. Warmerdam, Tom Rozema, HA A. Maurits Swellengrebel, Henk K Van Halteren, Ate van der Gaast, Marcel Verheij, Richard Van Hilligersberg, Helene Hörberg, Pehr Lind, Annemieke Cats, Cornelis J.H. van de Velde, Jitty M Smit, Alex L. T. Imholz, Donald L. van der Peet, Aart Van Bochove, Henk M.W. Verheul, Adelheid Me Van der Torren-Conze, Frans L. G. Erdkamp, Dick Johan van Spronsen, Mark I. van Berge Henegouwen, Ernst Jan Spillenaar Bilgen, Johanna Mgh Van Riel, Marien O Den Boer, Hanneke W. M. van Laarhoven, Marjolein Em Rentinck, Ron C Rietbroek, Bengt Johansson, David Borg, Anders Johnsson, Aart Beeker, Reinoud J. B. Blaisse, Miriam Koopman, Daan Ten Bokkel Huinink, Karen J. Neelis, Elma Meershoek-Klein Kranenbarg, Djamila Boerma, Heleen M. Ceha, Bea C Tanis, Marie-Cecile Jc Legdeur, O Aart Van Dobbenburgh, Steven Vanhoutvin, Sjoerd Hovenga, Karolina Sikorska, Pètra M Braam, H Pieter van den Berg, Huub van der Mijle, Marianne Nordsmark, Bengt Glimelius
Publikováno v:
lancet oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet Oncology, 19, 5, pp. 616-628
CRITICS investigators 2018, ' Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)-an international, open-label, randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 5, pp. 616-628 . https://doi.org/10.1016/S1470-2045(18)30132-3
Lancet oncology, 19(5), 616-628. Elsevier Science
Lancet Oncology, 19, 616-628
The Lancet Oncology, 19(5), 616-628
The Lancet Oncology, 19(5), 616-628. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: Both perioperative chemotherapy and postoperative chemoradiotherapy improve survival in patients with resectable gastric cancer from Europe and North America. To our knowledge, these treatment strategies hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b21019f3b155741c37a17771cdb957cb
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
https://pure.amc.nl/en/publications/chemotherapy-versus-chemoradiotherapy-after-surgery-and-preoperative-chemotherapy-for-resectable-gastric-cancer-critics-an-international-openlabel-randomised-phase-3-trial(8c4f223a-519d-480e-ad66-3d7eaea704e6).html
Autor:
Alfons J.M. van den Eertwegh, Joyce M. van Dodewaard-de Jong, Haiko J. Bloemendal, H. Pieter van den Berg, Daniela E. Oprea-Lager, Joe M. O'Sullivan, Otto S. Hoekstra, Aart Beeker, Henk M.W. Verheul, Marianne A. Jonker, John M. H. de Klerk, Maartje Los
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging, 44, 1319-1327
van Dodewaard-de Jong, J M, de Klerk, J M H, Bloemendal, H J, Oprea-Lager, D E, Hoekstra, O S, van den Berg, H P, Los, M, Beeker, A, Jonker, M A, O’Sullivan, J M, Verheul, H M W & van den Eertwegh, A J M 2017, ' A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 8, pp. 1319-1327 . https://doi.org/10.1007/s00259-017-3673-9
European Journal of Nuclear Medicine and Molecular Imaging, 44(8), 1319-1327. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 44, 8, pp. 1319-1327
van Dodewaard-de Jong, J M, de Klerk, J M H, Bloemendal, H J, Oprea-Lager, D E, Hoekstra, O S, van den Berg, H P, Los, M, Beeker, A, Jonker, M A, O’Sullivan, J M, Verheul, H M W & van den Eertwegh, A J M 2017, ' A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 8, pp. 1319-1327 . https://doi.org/10.1007/s00259-017-3673-9
European Journal of Nuclear Medicine and Molecular Imaging, 44(8), 1319-1327. Springer Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 44, 8, pp. 1319-1327
Item does not contain fulltext BACKGROUND: Rhenium-188-HEDP is a beta-emitting radiopharmaceutical used for palliation of metastatic bone pain. We investigated whether the addition of rhenium-188-HEDP to docetaxel/prednisone improved efficacy of chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbd9c0a9050a38fb73722c556133f90c
http://hdl.handle.net/2066/174735
http://hdl.handle.net/2066/174735
Autor:
Igle J. de Jong, Emile D. Kerver, Andries M. Bergman, Sushil K Badrising, H. Pieter van den Berg, Paul Hamberg, Harm van Tinteren, Jules L.L.M. Coenen, Inge M. van Oort, Alfons J.M. van den Eertwegh, Vincent van der Noort, Maartje Los
Publikováno v:
Cancer. 120:968-975
BACKGROUND: Enzalutamide (Enz) and abiraterone acetate (AA) are hormone treatments that have a proven survival advantage in patients with metastatic, castration-resistant prostate cancer who previously received docetaxel (Doc). Recently, limited acti
Autor:
Alfons J.M. van den Eertwegh, Thomas Harding, Natalie Sacks, Saskia J. A. M. Santegoets, R. Jeroen A. van Moorselaar, Kristen Hege, Rik J. Scheper, Israel Lowy, Winald R. Gerritsen, Tim M. van der Sluis, Herbert M. Pinedo, Karin Jooss, Anita G.M. Stam, Jurjen Versluis, B. Mary E. von Blomberg, H Pieter van den Berg, Tanja D. de Gruijl, H.E. Gall
Publikováno v:
van den Eertwegh, A J M, Versluis, J P, van den Berg, H P, Santegoets, S J A M, van Moorselaar, R J A, van der Sluis, T M, Gall, H E, Harding, T C, Jooss, K, Lowy, I, Pinedo, H M, Scheper, R J, Stam, A G M, von Blomberg, B M E, de Gruijl, T D, Hege, K, Sacks, N & Gerritsen, W R 2012, ' Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial ', Lancet Oncology, vol. 13, no. 5, pp. 509-517 . https://doi.org/10.1016/S1470-2045(12)70007-4
Lancet Oncology, 13, 5, pp. 509-17
Lancet Oncology, 13, 509-17
Lancet Oncology, 13(5), 509-517. Lancet Publishing Group
Lancet Oncology, 13, 5, pp. 509-17
Lancet Oncology, 13, 509-17
Lancet Oncology, 13(5), 509-517. Lancet Publishing Group
Item does not contain fulltext BACKGROUND: The granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) has antitumour activity against prostate cancer; preclinical studies have shown potent synergy
Publikováno v:
International Journal of Performance Analysis in Sport. 11:344-355
The objective of this study was to determine the movement patterns, heart rate recordings and work-to-rest ratios for different refereeing panels of South African Rugby Union referees during match-...
Autor:
H. Pieter van den Berg, Carolien H. Smorenburg, Alfonsus J. M. van den Eertwegh, Linda de Munck, Henk M.W. Verheul, Esther W. Bouman-Wammes, Winald R. Gerritsen, Aart Beeker
Publikováno v:
Journal of Clinical Oncology. 35:166-166
166 Background: Docetaxel is the standard first-line chemotherapy for patients with castration resistant prostate carcinoma (CRPC). Docetaxel re-challenge has never been tested in a prospective randomized clinical trial. As some studies supported the
Autor:
Sushil, Badrising, Vincent, van der Noort, Inge M, van Oort, H Pieter, van den Berg, Maartje, Los, Paul, Hamberg, Jules L, Coenen, Alfons J M, van den Eertwegh, Igle J, de Jong, Emile D, Kerver, Harm, van Tinteren, Andries M, Bergman
Publikováno v:
Cancer. 120(7)
Enzalutamide (Enz) and abiraterone acetate (AA) are hormone treatments that have a proven survival advantage in patients with metastatic, castration-resistant prostate cancer who previously received docetaxel (Doc). Recently, limited activity of AA a
Autor:
Joyce M. van Dodewaard-de Jong, Haiko Bloemendal, John M. H. de Klerk, Daniela E Oprea-Lager, Otto S. Hoekstra, H Pieter van den Berg, Maartje Los, Aart Beeker, Joe M. O'Sullivan, Henk M.W. Verheul, Alfonsus Johannes Maria van den Eertwegh
Publikováno v:
Journal of Clinical Oncology. 34:5081-5081
5081Background: Docetaxel is first line chemotherapy in CRPC. Re-188 is a beta-emitting radiopharmaceutical that targets bone metastases. We investigated whether treatment with docetaxel plus Re-18...